- Home
- HCWB
HCWB
HCW Biologics Inc.
as 02-21-2025 4:00pm EST
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | MIRAMAR |
| Market Cap: | 17.2M | IPO Year: | 2021 |
| Target Price: | N/A | AVG Volume (30 days): | 18.3M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.00 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.21 - $2.52 | Next Earning Date: | 03-31-2025 |
| Revenue: | $3,495,990 | Revenue Growth: | 22.27% |
| Revenue Growth (this year): | 229.19% | Revenue Growth (next year): | N/A |
Latest HCW Biologics Inc. News
HCWB Breaking Stock News: Dive into HCWB Ticker-Specific Updates for Smart Investing
MT Newswires
19 days ago
Top Midday Gainers
MT Newswires
20 days ago
HCW Biologics Says FDA Approves Trial of HCW9302 to Treat Alopecia Areata; Shares Rise Pre-Bell
GlobeNewswire
20 days ago
HCW Biologics Granted FDA Clearance to Evaluate One of the Company’s Lead Product Candidates in a First-In-Human Phase 1 Clinical Trial
Simply Wall St.
a month ago
HCW Biologics Insiders Placed Bullish Bets Worth US$2.50m
GlobeNewswire
a month ago
HCW Biologics’ Founder and CEO to Address Opportunities and Challenges in Biomanufacturing for Cell and Gene Therapies During J.P. Morgan Week in San Francisco on January 15, 2025
MT Newswires
2 months ago
HCW Biologics Shares Fall Amid Delisting Notice From Nasdaq
GlobeNewswire
2 months ago
HCW Biologics Inc. Received NASDAQ Staff Determination Letter
TipRanks
3 months ago
HCW Biologics prices $6.9M registered direct offering at $1.03 per share
Compare HCWB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HCWB HCW Biologics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.